PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11855668-1	2002	The present study was designed to examine whether long-term blockade of angiotensin-converting enzyme (ACE) with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease (CAD).	Dobutamine	137-147	angiotensin I converting enzyme	Homo sapiens	72-101	
18375318-12	2008	ACE-Is were well tolerated in all patients in group R. CONCLUSIONS: ACE-Is can be used as a dobutamine substitute as early as the first postoperative day after cardiac surgery without renal consequences.	Dobutamine	92-102	angiotensin I converting enzyme	Homo sapiens	0-3	
18375318-12	2008	ACE-Is were well tolerated in all patients in group R. CONCLUSIONS: ACE-Is can be used as a dobutamine substitute as early as the first postoperative day after cardiac surgery without renal consequences.	Dobutamine	92-102	angiotensin I converting enzyme	Homo sapiens	68-71	
11855668-1	2002	The present study was designed to examine whether long-term blockade of angiotensin-converting enzyme (ACE) with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease (CAD).	Dobutamine	137-147	angiotensin I converting enzyme	Homo sapiens	103-106	
11288970-2	2001	HYPOTHESIS: We hypothesized that the inotropic support afforded by dobutamine may serve as a bridge to the introduction and intensification of angiotensin-converting enzyme (ACE) inhibitor-nitrate therapy.	Dobutamine	67-77	angiotensin I converting enzyme	Homo sapiens	143-172	
11288970-2	2001	HYPOTHESIS: We hypothesized that the inotropic support afforded by dobutamine may serve as a bridge to the introduction and intensification of angiotensin-converting enzyme (ACE) inhibitor-nitrate therapy.	Dobutamine	67-77	angiotensin I converting enzyme	Homo sapiens	174-177	
11288970-12	2001	CONCLUSIONS: Of the patients on dobutamine inotropic support, 70% were successfully transitioned to ACE inhibitor-nitrate therapy, with improved symptoms and LVEF, and with reduced hospitalizations and follow-up dobutamine or transplant.	Dobutamine	32-42	angiotensin I converting enzyme	Homo sapiens	100-103	
11288970-12	2001	CONCLUSIONS: Of the patients on dobutamine inotropic support, 70% were successfully transitioned to ACE inhibitor-nitrate therapy, with improved symptoms and LVEF, and with reduced hospitalizations and follow-up dobutamine or transplant.	Dobutamine	212-222	angiotensin I converting enzyme	Homo sapiens	100-103	
10520782-0	1999	Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat IV: a study using [15O] water dobutamine stress positron emission tomography.	Dobutamine	148-158	angiotensin I converting enzyme	Homo sapiens	60-89	
10520782-7	1999	In contrast, MBF in ischemic regions increased significantly after acute ACE inhibition with quinaprilat during repetitive dobutamine stress (1.10 +/- 0.13 vs. 1.69 +/- 0.17 ml/min/g, p < 0.015).	Dobutamine	123-133	angiotensin I converting enzyme	Homo sapiens	73-76	
34487814-9	2022	Dobutamine and nitroprusside treatment decreased the transrenal gradient of ACE (p=0.012, p<0.0001 respectively), aldosterone (p=0.005, p=0.030) and PRA (p=0.014, p=0.002) in patients with HF only.	Dobutamine	0-10	angiotensin I converting enzyme	Homo sapiens	76-79